Physician profile
Stephanie Moore
NPI 1740261486
$30,130.00
in general payments reported to CMS, 2019-2025
26 companies · $13K in 2025
The $13K reported for 2025 was more than what 80% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $451 · 2022: $1,361 · 2023: $793 · 2024: $15K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $2,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,720.00 |
| Food and Beverage | $2,598.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21,234.77 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $5,200.00 | 2024-2025 | Jardiance |
| Abiomed | $568.70 | 2021-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $459.27 | 2021-2025 | Lifevest |
| Abbott Laboratories | $375.91 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Actelion Pharmaceuticals US, INC. | $266.84 | 2023-2025 | Uptravi, Opsumit |
| Alnylam Pharmaceuticals INC. | $251.26 | 2022-2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $244.26 | 2021-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $217.63 | 2022-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $177.19 | 2021-2025 | Verquvo, Winrevair |
| Vifor Pharma, INC. | $170.98 | 2022-2023 | Veltassa |
| Medtronic, INC. | $141.20 | 2022-2024 | Hvad Pump Implant Kit, Aurora Ev-Icd Mri Surescan |
| Daxor Corporation | $129.32 | 2022 | |
| Pfizer INC. | $120.65 | 2023-2025 | |
| Novo Nordisk INC | $118.91 | 2023-2025 | Ozempic, Rybelsus |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $100.71 | 2022-2024 | |
| Lexicon Pharmaceuticals, INC. | $76.14 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $53.32 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $51.24 | 2022 | |
| Cvrx, INC. | $42.54 | 2022 | |
| Bsn Medical INC | $23.63 | 2023 | |
| Medline Industries LP | $22.61 | 2023 | |
| Janssen Pharmaceuticals, INC | $22.61 | 2022 | |
| Baxter Healthcare | $21.70 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Masimo Corporation | $20.72 | 2024 | |
| Boston Scientific Corporation | $17.89 | 2024 | Bodyguardian |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.